Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | ACR | P10323 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145992 | 0.85 | CA1 (0.46) | CA1CA2CA12CA9CA14 | |
| SCHEMBL3539591 | 0.81 | SLC7A5 (0.45) | CA1CA2CA12CA9CA14 | |
| SCHEMBL22010015 | 0.81 | CA1 (0.49) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1421354 | 0.81 | RAB9A (0.56) | CA1CA2CA12CA9CA14 | |
| SCHEMBL25611100 | 0.81 | CA1 (0.43) | CA1CA2CA12CA9CA14 | |
| SCHEMBL9748412 | 0.80 | HSD17B10 (0.46) | CA1CA2HSD17B10P2RY6PRSS1 | |
| SCHEMBL109451 | 0.80 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL12369105 | 0.79 | CA1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL23865008 | 0.77 | CA1 (0.49) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1457515 | 0.77 | MAPT (0.56) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (WUXI) COMPANY, INC. (CN) | 2016-09-01 | — | — | US | claimed |
| EP-3034076-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (Wuxi) COMPANY, Inc. (CN) | 2016-06-22 | — | — | EP | claimed |
| EP-3446689-B1 | ISOTHIOCYANATE COMPOUND FOR USE IN THE TREATMENT OF HYPERBILIRUBINEMIA | JC WUXI COMPANY INC (CN) | 2025-01-08 | — | — | EP | disclosed |
| CN-113262218-B | Use of isothiocyanate compounds | 无锡杰西医药股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| CN-115429785-A | Composition for improving bioavailability and treatment effect of isothiocyanate compounds | 无锡杰西医药股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-11298334-B2 | Use of isothiocyanate compounds | JC (WUXI) COMPANY, INC. (CN) | 2022-04-12 | — | — | US | disclosed |
| WO-2021229035-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2021-11-18 | — | — | WO | disclosed |
| CN-104173272-B | Sustained-release preparation of isothiocyanate compounds | 无锡杰西医药股份有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-104117064-B | Combined application of isothiocyanate compounds and hormone drugs | 无锡杰西医药股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20190142780-A1 | USE OF ISOTHIOCYANATE COMPOUNDS | JC (WUXI) COMPANY, INC. (CN) | 2019-05-16 | — | — | US | disclosed |
| US-20080306063-A1 | PHENYLAMINO ISOTHIAZOLE CARBOXAMIDINES AS MEK INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-7429667-B2 | Phenylamino isothiazole carboxamidines as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429667-B2 | Phenylamino isothiazole carboxamidines as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060194802-A1 | Phenylamino isothiazole carboxamidines as MEK inhibitors | ARDEA BIOSCIENCES, INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1438046-A4 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1438046-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6720346-B2 | (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS | AGOURON PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003004467-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | CHUK, KIT, MKI67 | CA1 1745/4885CA2 924/4885CA12 1582/4885 |
| US-11298334-B2 | Use of isothiocyanate compounds | LIPC, CETP, LCAT | CA1 4418/4885CA2 4406/4885CA12 3660/4885 |
| US-20080306063-A1 | PHENYLAMINO ISOTHIAZOLE CARBOXAMIDINES AS MEK INHIBITORS | BRAF, MAP4K2, MAP3K4 | CA1 4678/4885CA2 4195/4885CA12 4818/4885 |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | CA1 3551/4885CA2 1112/4885CA12 3814/4885 |
| US-20060194802-A1 | Phenylamino isothiazole carboxamidines as MEK inhibitors | BRAF, MAP4K2, MAP3K4 | CA1 4678/4885CA2 4195/4885CA12 4818/4885 |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | CA1 3995/4885CA2 4224/4885CA12 3662/4885 |
| US-20190142780-A1 | USE OF ISOTHIOCYANATE COMPOUNDS | LIPC, CETP, LCAT | CA1 4418/4885CA2 4406/4885CA12 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.